Literature DB >> 26742628

Expression and regulation of the estrogen receptors in PC-3 human prostate cancer cells.

R Pisolato1, A P G Lombardi1, C M Vicente1, T F G Lucas1, M F M Lazari1, C S Porto2.   

Abstract

The aim of this study was to identify the expression, cellular localization and regulation of classic estrogen receptors ERα and ERβ, ER-α36 isoform and GPER in the androgen-independent prostate cancer cell line PC-3. In addition, we evaluated the relative contribution of these receptors to the activation of the ERK1/2 (extracellular signal-regulated protein kinases) signaling pathway. These four estrogen receptors were detected by Western blot assays and were shown by immunofluorescence assays to localize preferentially in extranuclear regions of PC-3 cells. In addition, treatment with 17β-estradiol (E2) (1 μM) for 24 h led to down-regulation of the classic estrogen receptors, whereas E2 at physiological concentration (0.1 nM) for 24h tended to increase the levels of ERα and ERβ. Furthermore, the ERα-selective agonist PPT selectively increased the expression of ERβ and the ERβ-selective agonist DPN increased ERα levels. None of these treatments affected expression of the ER-α36 isoform. The unusual cytoplasmic localization of the classic estrogen receptors in these cells differs from the nuclear localization in the majority of estrogen target cells and suggests that rapid signaling pathways may be preferentially activated. In fact, treatment with selective agonists of ERα, ERβ and GPER induced ERK1/2 phosphorylation that was blocked by the respective antagonists. On the other hand, activation of ERK1/2 induced by E2 may involve additional mechanisms because it was not blocked by the three antagonists. Taken together, the results indicate that there is a crosstalk between ERα and ERβ to regulate the expression of each other, and suggest the involvement of other receptors, such as ER-α36, in the rapid ERK1/2 activation by E2. The identification of new isoforms of ERs, regulation of the receptors and signaling pathways is important to develop new therapeutic strategies for the castration-resistant prostate cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ER-α36; ERK1/2; Estrogen receptors α and β; GPER; PC-3 cells

Mesh:

Substances:

Year:  2015        PMID: 26742628     DOI: 10.1016/j.steroids.2015.12.021

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  10 in total

Review 1.  Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity.

Authors:  Matthew W Boudreau; Paul J Hergenrother
Journal:  RSC Med Chem       Date:  2022-05-09

2.  Brazilian Berry Extract Differentially Induces Inflammatory and Immune Responses in Androgen Dependent and Independent Prostate Cancer Cells.

Authors:  Larissa Akemi Kido; Isabela Maria Urra Rossetto; Andressa Mara Baseggio; Gabriela Bortolanza Chiarotto; Letícia Ferreira Alves; Felipe Rabelo Santos; Celina de Almeida Lamas; Mário Roberto Maróstica Jr; Valéria Helena Alves Cagnon
Journal:  J Cancer Prev       Date:  2022-09-30

3.  Estrogen Receptors Promote Migration, Invasion and Colony Formation of the Androgen-Independent Prostate Cancer Cells PC-3 Through β-Catenin Pathway.

Authors:  Ana Paola G Lombardi; Carolina M Vicente; Catarina S Porto
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-09       Impact factor: 5.555

4.  Anisodamine Ameliorates Hyperkalemia during Crush Syndrome through Estradiol-Induced Enhancement of Insulin Sensitivity.

Authors:  Jian-Guang Yu; Bo-Shi Fan; Jin-Min Guo; Yun-Jie Shen; Ye-Yan Hu; Xia Liu
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

5.  Estrogen Receptor Signaling Pathways Involved in Invasion and Colony Formation of Androgen-Independent Prostate Cancer Cells PC-3.

Authors:  Ana Paola G Lombardi; Renan P Cavalheiro; Catarina S Porto; Carolina M Vicente
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

Review 6.  Distribution and Effects of Estrogen Receptors in Prostate Cancer: Associated Molecular Mechanisms.

Authors:  Adrián Ramírez-de-Arellano; Ana Laura Pereira-Suárez; Cecilia Rico-Fuentes; Edgar Iván López-Pulido; Julio César Villegas-Pineda; Erick Sierra-Diaz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-11       Impact factor: 5.555

Review 7.  Selective estrogen receptor modulators contribute to prostate cancer treatment by regulating the tumor immune microenvironment.

Authors:  Dali Tong
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751

Review 8.  Molecular Mechanism of Tanshinone against Prostate Cancer.

Authors:  Wei Li; Tao Huang; Shenghan Xu; Bangwei Che; Ying Yu; Wenjun Zhang; Kaifa Tang
Journal:  Molecules       Date:  2022-08-30       Impact factor: 4.927

Review 9.  Estrogen Receptors in Epithelial-Mesenchymal Transition of Prostate Cancer.

Authors:  Erika Di Zazzo; Giovanni Galasso; Pia Giovannelli; Marzia Di Donato; Antonio Bilancio; Bruno Perillo; Antonio A Sinisi; Antimo Migliaccio; Gabriella Castoria
Journal:  Cancers (Basel)       Date:  2019-09-23       Impact factor: 6.639

10.  Lipocalin-2 (LCN2) Deficiency Leads to Cellular Changes in Highly Metastatic Human Prostate Cancer Cell Line PC-3.

Authors:  Sarah K Schröder; Manuela Pinoé-Schmidt; Ralf Weiskirchen
Journal:  Cells       Date:  2022-01-13       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.